FUTURE STUDIES

Two studies are in the pipeline.
PAVE 100: is a consortium of networks' Proof of concept study that will test a Multicade 6 plasmid DNA prime boosted by a recombinant multi-clade adeno5 vectored vaccine.

A total of 8500 will be enrolled, out of which MUWRP will contribute 700 participants

RV 217: HIV-1 Prevalence, Incidence, Cohort Retention, and Host Genetics
and Viral Diversity in High Risk Cohorts in East Africa

This is a multi-site high risk cohort that will enroll 1500 from the three East African USMHRP sites. MUWRP will contribute a third of these participants